An interventional study of Nicoderm CQ nicotine patch and Nicorette Nicotine Lozenges in Smoking Cessation, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 2 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Masonic Cancer Center, University of Minnesota · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.
Among the 920 studies in Smoking Cessation with a site in United States, this one is the 191st largest by planned enrollment of the 872 interventional ones that give a count, is one of 37 that started in 2026, is one of 512 with no phase, reaches primary completion later than 107 of the 125 other live ones, and was the 850th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 21 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
920 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 138 · Phase 3 91 · Phase 4 99
First in 1996; this study’s year is marked. 37 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 544 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 149 across the 872 interventional studies, 200 across the 45 observational. Of the 756 that completed or were terminated, 376 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 920 have an industry lead sponsor. The 10 most frequent:
Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
Masonic Cancer Center, University of Minnesota has 3 studies filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
54 of the studies in Smoking Cessation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT00591175Memorial Sloan Kettering Cancer CenterA Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 54 to your calendar (.ics) → With an account.
Among the 920 studies in Smoking Cessation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Understanding ways to help people who live in rural areas quit smoking is a public health priority. quitting smoking among rural people who smoke is a critical public health concern. People in rural areas smoke at higher rates than those in urban areas, experience high rates of smoking caused cancers and deaths. We are recruiting rural people from around the country to better understand how different quit smoking methods can improve a person's chances of successfully quitting smoking.
This is a SMART, where eligible rural people who smoke (RPWS) can be randomized up to two times to different resources/ways to help quit smoking. For each randomization, participants will use the assigned resources for 3 months, and partake in surveys at baseline, 1, and 3 months, during which they will be asked several questions related to use of resources, and smoking behavior. Carbon monoxide (CO) in exhaled breath will be collected at 3 months using iCO™ Smokerlyzer® (https://www.icoquit.com/us/) to determine biochemically confirmed abstinence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly text and email messages referring to Smokefree.gov, NRT Starter kit, free 2-week supply of patches (Nicoderm CQ in either 21 or 14 mg nicotine) and lozenges (Nicorette Nicotine Lozenges, Mint Flavor in either 4 or 2 mg nicotine) with NRT education plus referral to where to request more NRT.
Drug: Nicoderm CQ nicotine patch · Drug: Nicorette Nicotine Lozenges
Weekly text and email messages referring to Smokefree.gov
Weekly text and email messages on reduced harm or exposure (RHE) tobacco products.
Two week supply provided to participants on study.
Two week supply provided to participants on study.
Number of participants abstinent from all combustible tobacco products
Biochemically-confirmed 7-day abstinence from all combustible tobacco products at 3 months.
Time frame: 3 months
Cigarettes per day (CPD)
Number of cigarettes smoked per day.
Time frame: 1 and 3 months
Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.
Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 30 months is above that.
Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Masonic Cancer Center, University of Minnesota →